~~**We claim:**~~ **Claims:**

~~1. A pharmaceutical combination comprising an anti-CD19 antibody and R-CHOP for use in the treatment of patients with DLBCL.~~

~~2. The pharmaceutical combination according to claim 1 for use in the treatment of patients with DLBCL comprising administering to the patient a therapeutic amount of:~~

~~an anti-CD19 antibody;~~

~~rituximab;~~

~~cyclophosphamide;~~

~~doxorubicin;~~

~~vincristine; and~~

~~prednisone or prednisolone.~~

1. Use of an anti-CD19 antibody in the manufacture of a medicament for treating DLBCL in a patient, wherein the medicament is to be administered in combination with R-CHOP.

2. Use of an anti-CD19 antibody in the manufacture of a medicament for treating DLBCL in a patient, wherein the medicament is to be administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone.

3. ~~The pharmaceutical combination according to~~ The use of claim 2 ~~for use in the treatment of patients with DLBCL comprising administering to~~, wherein the patient is to be administered in at least one 21-day cycle a combination of:

~~an~~the anti-CD19 antibody on day 1, day 8, and day 15 of the 21-day cycle;

rituximab on day 1 of the 21-day cycle;

cyclophosphamide on day 1 of the 21-day cycle;

doxorubicin on day 1 of the 21-day cycle;

vincristine on day 1 of the 21-day cycle; and

prednisone or prednisolone on each of days 1 to 5 of the 21-day cycle.

4. ~~The pharmaceutical combination~~ use according to claim 3 ~~for use in the treatment of patients with DLBCL comprising administering to~~, wherein the patient is to be administered at least three 21-day cycles of the combination.

5. ~~——~~ The ~~pharmaceutical combination~~ use according to claim 3 ~~for use in the treatment of patients with DLBCL comprising administering to~~ , wherein the patient is to be administered at least six 21-day cycles of the combination.

6. ~~——~~ The ~~pharmaceutical combination~~ use according to claim 2 ~~for use in the treatment of patients with DLBCL comprising administering to~~ , wherein the patient is to be administered a combination of:

~~an~~the anti-CD19 antibody;

rituximab in a 375 mg/m^2 dose;

cyclophosphamide in a 750 mg/m^2 dose;

doxorubicin in a 50 mg/m^2 dose;

vincristine in a 1.4 to 2.0 mg/m^2 dose; and

prednisone or prednisolone in a 100 mg dose.

7. ~~——~~ The ~~pharmaceutical combination~~ use according to claim 5~~ for use in the treatment of patients with DLBCL comprising administering to~~ , wherein the patient is to be administered in at least one 21-day cycle a combination of:

~~an~~the anti-CD19 antibody on day 1, day 8, and day 15 of the 21-day cycle;

rituximab in a 375 mg/m^2 dose on day 1 of the 21-day cycle;

cyclophosphamide in a 750 mg/m^2 dose on day 1 of the 21-day cycle;

doxorubicin in a 50 mg/m^2 dose on day 1 of the 21-day cycle;

vincristine in a 1.4 to 2.0 mg/m^2 dose on day 1 of the 21-day cycle; and

prednisone or prednisolone in a 100 mg dose on each of days 1 to 5 of the 21-day cycle.

8. ~~——~~ The ~~pharmaceutical combination~~ use according to claim 7~~ for use in the treatment of patients with DLBCL comprising administering to~~ , wherein the patient is to be administered at least three 21-day cycles of the combination.

9. ~~——~~ The ~~pharmaceutical combination~~ use according to claim 7~~ for use in the treatment of patients with DLBCL comprising administering to the~~ , wherein the patient is to be administered at least six 21-day cycles of the combination.

10. ~~——~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims~~ for use in the treatment of patients with DLBCL,~~ wherein the anti-CD19 antibody is to be administered in a body weight dose of 8~~ ~~mg/kg to 40~~ ~~mg/kg.

11. ~~——~~ The ~~pharmaceutical combination~~ anti-use according to claim 9~~ for use in the treatment of patients with DLBCL,~~ wherein the anti-CD19 antibody is to be administered in a body weight dose of 12~~ ~~mg/kg.

12. ~~——~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims~~ for use in the treatment of patients with DLBCL,~~ wherein the ~~pharmaceutical combination~~ treatment further comprises lenalidomide.

13. ~~—~~ The ~~pharmaceutical combination~~ use according to claim 12 ~~for use in the treatment of patients with DLBCL,~~ wherein lenalidomide is to be administered in a 25- mg dose.

14. ~~—~~ The ~~pharmaceutical combination~~ use according to claim 12 ~~for use in the treatment of patients with DLBCL,~~ wherein lenalidomide is to be administered to the patient in at least one 21-day cycle in a 25- mg dose on each of days 1 to 10 of the 21-day cycle.

15. ~~—~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims ~~for use in~~, wherein the treatment ~~of patients with DLBCL~~ further ~~comprising the administration of~~comprises granulocyte colony stimulating factor (G-CSF) or pegylated G-CSF.

16. ~~—~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims ~~for use in the treatment of patients with DLBCL~~, wherein administration of the combination leads to a complete response (CR) in the patient.

17. The ~~pharmaceutical combination~~use according to any one of the preceding claims, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO:1);

the VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO:2); and

the VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO:3); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4);

the VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO:5); and

the VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO:6).

18. ~~—~~ The ~~pharmaceutical combination~~use according to claim 17 ~~for use in the treatment of patients with DLBCL~~, wherein the VH domain comprises the amino acid sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDG TKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGT LVTVSS (SEQ ID NO:7) and the VL domain comprises the amino acid sequence

DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID
NO:8).

19. ~~—~~ The ~~pharmaceutical combination~~ use according to claim 18 ~~for use in the treatment of patients with DLBCL~~, wherein the anti-CD19 antibody comprises a heavy chain region of

EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINP
YNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYW
GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQ
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:-11)
and a light chain region of
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPSV
FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:-12).

20. ~~—~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims ~~for use in the treatment of patients with DLBCL~~, wherein the ~~patients are patients with~~patient has previously untreated DLBCL.

21. ~~—~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims ~~for use in the treatment of patients with DLBCL~~, wherein the ~~patients have~~patient has an International Prognostic Index (IPI) status of 2-5, 3-5, 4-5, 3-4, 3, 4, or 5 prior to starting the ~~administering~~treatment.

22. ~~—~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims ~~for use in the treatment of patients with DLBCL~~, wherein the ~~patients have~~patient has Stage III or Stage IV DLBCL prior to starting the ~~administering~~treatment.

23. ~~—~~ The ~~pharmaceutical combination~~ use according to any one of the preceding claims ~~for use in the treatment of patients with DLBCL~~, wherein the anti-CD19 antibody is tafasitamab.

~~24. A method of treating a patient with DLBCL comprising administering to the patient a pharmaceutical combination according to any of the preceding claims.~~

~~25~~ 24. ~~.~~ Use of an anti-CD19 antibody in the manufacture of a medicament for~~A method of~~ treating a non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia in a human subject in need thereof, wherein the ~~method comprising~~

~~administering~~medicament is to ~~the human subject a therapeutically effective amount of an antibody that binds to human CD19,~~be administered in combination with lenalidomide~~,~~ and rituximab.

25. ~~26.~~ The ~~method of~~use according to claim ~~25~~24, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO:1);

the VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO:2); and

the VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO:3); and

wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4);

the VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO:5); and

the VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO:6).

26. ~~27.~~ The ~~method of~~use according to claim 25~~ or claim 26~~, wherein the VH domain comprises the amino acid sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDG TKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGT LVTVSS (SEQ ID NO:7) and the VL domain comprises the amino acid sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO:8).

27. ~~28.~~ The ~~method of any one of claims 25~~use according to ~~27~~claim 26, wherein the anti-CD19 antibody comprises a heavy chain region of

EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINP YNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYW GQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV

HNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQ
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSD
GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:-11)
and a light chain region of
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL
NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPSV
FI

FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:-12).

28. ~~29.~~ The ~~method of~~ use according to any one of claims ~~25~~24 to ~~28~~26, wherein the human subject has a non-Hodgkin lymphoma.

29. ~~30.~~ The ~~method~~use according to claim ~~29~~28, wherein the non-Hodgkin lymphoma is follicular lymphoma.

30. ~~31.~~ The ~~method of~~use according to claim ~~30~~29, wherein the follicular lymphoma is relapsed/refractory follicular lymphoma.

~~32.~~ 31. The ~~method of~~use according to claim ~~30~~29 or ~~31~~30, wherein the follicular lymphoma is histologically confirmed Grade 1, 2, or 3a follicular lymphoma.

32. ~~33.~~ The ~~method~~use according to claim ~~29~~28, wherein the non-Hodgkin lymphoma is marginal zone lymphoma.

33. ~~34.~~ The ~~method of~~use according to claim ~~33~~32, wherein the marginal zone lymphoma is relapsed/refractory marginal zone lymphoma.

~~35.~~ 34. The ~~method of~~use according to claim ~~33~~32 or ~~34~~33, wherein the marginal zone lymphoma is histologically confirmed nodal marginal zone lymphoma, splenic marginal zone lymphoma, or extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue.

35. ~~36.~~ The ~~method~~ use according to claim ~~29~~28, wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma.

36. ~~37.~~ The ~~method of~~ use according to claim ~~36~~35, wherein the diffuse large B-cell lymphoma is relapsed/refractory diffuse large B-cell lymphoma.

37. ~~38.~~ The ~~method~~ use according to claim ~~29~~28, wherein the non-Hodgkin lymphoma is small lymphocytic lymphoma.

38. ~~39.~~ The ~~method~~ use according to claim ~~29~~28, wherein the non-Hodgkin lymphoma is mucosa-associated lymphoid tissue lymphoma.

39. ~~40.~~ The ~~method~~ use according to claim ~~29~~28, wherein the non-Hodgkin lymphoma is Burkitt's lymphoma.

40. ~~41.~~ The ~~method~~ use according to claim ~~29~~28, wherein the non-Hodgkin lymphoma is mantle cell lymphoma.

41. ~~42.~~ The ~~method of~~ use according to any one of claims ~~25~~24 to ~~28~~27, wherein the human subject has chronic lymphocytic leukemia.

42. ~~43.~~ The ~~method of~~use according to any one of claims ~~25~~24 to ~~28~~27, wherein the human subject has acute lymphoblastic leukemia.

43. ~~44.~~ The ~~method of~~ use according to any one of claims ~~25~~24 to ~~43~~42, wherein the antibody is to be administered intravenously.

44. ~~45.~~ The ~~method of~~use according to any one of claims ~~25~~24 to ~~43~~42, wherein the antibody is to be administered intravenously at a dose of 12 mg/kg.

45. ~~46.~~ The ~~method of~~use according to any one of claims ~~25~~24 to ~~43~~42, wherein the antibody is to be administered intravenously at least once every two weeks at a dose of 12 mg/kg.

~~47.~~ 46. The ~~method of~~use according to any one of claims ~~25~~24 to ~~43~~42, wherein the antibody is to be administered intravenously at a dose of 12 mg/kg according to the following schedule:

on days 1, 8, 15, and 22 of a first 28-day cycle;

on days 1, 8, 15, and 22 of a second 28-day cycle;

on days 1, 8, 15, and 22 of a third 28-day cycle; and

on days 1 and 15 of a fourth 28-day cycle and on days 1 and 15 of further 28-day cycles thereafter.

47. ~~48.~~ The ~~method of any one of claims 25~~use according to ~~47~~any one of claims 24 to 46, wherein rituximab is to be administered intravenously.

48. ~~49.~~ The ~~method of~~ use according to any one of claims ~~25~~24 to ~~47~~46, wherein rituximab is to be administered intravenously at a dose of 375 mg/m^2.

~~50.~~ 49. The ~~method of~~ use according to any one of claims ~~25~~24 to ~~47~~46, wherein rituximab is to be administered intravenously at a dose of 375 mg/m^2 according to the following schedule:

on days 1, 8, 15, and 22 of a first 28-day cycle; and

on day 1 of a second 28-day cycle and on day 1 of further 28-day cycles thereafter.

50. ~~51.~~ The ~~method of~~ use according to any one of claims ~~25~~24 to ~~50~~49, wherein lenalidomide is to be administered orally.

51. ~~52.~~ The ~~method of~~ use according to any one of claims ~~25~~24 to ~~50~~49, wherein lenalidomide is to be administered orally at a dose of 20 mg.

52. ~~53.~~ The ~~method of~~ use according to any one of claims ~~25~~24 to ~~50~~49, wherein lenalidomide is to be administered orally at a dose of 20 mg on days 1-21 of repeated 28-day cycles.

53. ~~54. An~~Use of an anti-CD19 antibody ~~for use in~~ and use of R-CHOP for the preparation of a pharmaceutical combination for the treatment of patients with DLBCL ~~wherein the treatment also comprises R-CHOP~~.

~~55.~~ 54. The ~~anti-CD19 antibody~~use according to claim ~~54 for use in the treatment of patients with DLBCL~~53 wherein the ~~patient~~pharmaceutical combination is to be administered to the patient in a therapeutic amount of:

~~the~~an anti-CD19 antibody;

rituximab;

cyclophosphamide;

doxorubicin;

vincristine; and

prednisone or prednisolone.

~~56. The anti-CD19 antibody according to claim 55 for use in the treatment of patients with DLBCL wherein the patient is administered in at least one 21-day cycle a combination of:~~

~~the anti-CD19 antibody on day 1, day 8, and day 15 of the 21-day cycle;~~

~~rituximab on day 1 of the 21-day cycle;~~

~~cyclophosphamide on day 1 of the 21-day cycle;~~

~~doxorubicin on day 1 of the 21-day cycle;~~

~~vincristine on day 1 of the 21-day cycle; and~~

~~prednisone or prednisolone on each of days 1 to 5 of the 21-day cycle.~~

~~57. The anti-CD19 antibody according to claim 56 for use in the treatment of patients with DLBCL wherein the patient is administered at least three 21-day cycles of the combination.~~

~~58. The anti-CD19 antibody according to claim 56 for use in the treatment of patients with DLBCL wherein the patient is administered at least six 21-day cycles of the combination.~~

~~59. The anti-CD19 antibody according to claim 55 for use in the treatment of patients with DLBCL wherein the patient is administered a combination of:~~

~~the anti-CD19 antibody;~~

~~rituximab in a 375 mg/m^2 dose;~~

~~cyclophosphamide in a 750 mg/m^2 dose;~~

~~doxorubicin in a 50 mg/m^2 dose;~~

~~vincristine in a 1.4 to 2.0 mg/m^2 dose; and~~

~~prednisone or prednisolone in a 100 mg dose.~~

~~60. The anti-CD19 antibody according to claim 58 for use in the treatment of patients with DLBCL wherein the patient is administered in at least one 21-day cycle a combination of:~~

~~the anti-CD19 antibody on day 1, day 8, and day 15 of the 21-day cycle;~~

~~rituximab in a 375 mg/m^2 dose on day 1 of the 21-day cycle;~~

~~cyclophosphamide in a 750 mg/m^2 dose on day 1 of the 21-day cycle;~~

~~doxorubicin in a 50 mg/m^2 dose on day 1 of the 21-day cycle;~~

~~vincristine in a 1.4 to 2.0 mg/m^2 dose on day 1 of the 21-day cycle; and~~

~~prednisone or prednisolone in a 100 mg dose on each of days 1 to 5 of the 21-day cycle.~~

~~61. The anti-CD19 antibody according to claim 60 for use in the treatment of patients with DLBCL wherein the patient is administered at least three 21-day cycles of the combination.~~

~~62. The anti-CD19 antibody according to claim 60 for use in the treatment of patients with DLBCL wherein the patient is administered at least six 21-day cycles of the combination.~~

~~63. The anti-CD19 antibody according to any one of claims 54-62 for use in the treatment of patients with DLBCL wherein the anti-CD19 antibody is administered in a body weight dose of 8 mg/kg to 40 mg/kg.~~

~~64. The anti-CD19 antibody according to claim 62 for use in the treatment of patients with DLBCL wherein the anti-CD19 antibody is administered in a body weight dose of 12 mg/kg.~~

65. The anti-CD19 antibody according to any one of claims 54-64 for use in the treatment of patients with DLBCL wherein the treatment further comprises lenalidomide.

66. The anti-CD19 antibody according to claim 65 for use in the treatment of patients with DLBCL wherein lenalidomide is administered in a 25 mg dose.

67. The anti-CD19 antibody according to claim 65 for use in the treatment of patients with DLBCL wherein lenalidomide is administered to the patient in at least one 21-day cycle in a 25 mg dose on each of days 1 to 10 of the 21-day cycle.

68. The anti-CD19 antibody according to any one of claims 54-67 for use in the treatment of patients with DLBCL wherein the treatment further comprises granulocyte colony stimulating factor (G-CSF) or pegylated G-CSF.

69. The anti-CD19 antibody according to any one of claims 54-68 for use in the treatment of patients with DLBCL, wherein administration of the combination leads to a complete response (CR) in the patient.

70. The anti-CD19 antibody for use according to any one of claims 54-69, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO:1);
the VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO:2); and
the VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO:3); and
wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4);
the VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO:5); and
the VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO:6).

71. The anti-CD19 antibody according to claim 70 for use in the treatment of patients with DLBCL, wherein the VH domain comprises the amino acid sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDG
TKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQG

~~TLVTVSS (SEQ ID NO:7) and the VL domain comprises the amino acid sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL N~~

SGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO:8).

72. The anti-CD19 antibody according to claim 71 for use in the treatment of patients with DLBCL, wherein the anti-CD19 antibody comprises a heavy chain region of EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDG TKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDG SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 11) and a light chain region of DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12).

73. The anti-CD19 antibody according to any one of claims 54-72 for use in the treatment of patients with DLBCL, wherein the patients are patients with previously untreated DLBCL.

74. The anti-CD19 antibody according to any one of claims 54-73 for use in the treatment of patients with DLBCL, wherein the patients have an International Prognostic Index (IPI) status of 2-5, 3-5, 4-5, 3-4, 3, 4, or 5 prior to starting the administering.

75. The anti-CD19 antibody according to any one of claims 54-74 for use in the treatment of patients with DLBCL, wherein the patients have Stage III or Stage IV DLBCL prior to starting the administering.

76. The anti-CD19 antibody according to any one of claims 54-75 for use in the treatment of patients with DLBCL, wherein the anti-CD19 antibody is tafasitamab.

77. An anti-CD19 antibody for use in the treatment of a patient with DLBCL.

78. An antibody that binds to human CD19 for use in the treatment of a non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia in a human subject in need thereof, wherein the human subject is administered a therapeutically effective amount of the antibody that binds to human CD19, lenalidomide, and rituximab.

79. The antibody that binds to human CD19 for use according to claim 78, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence SYVMH (SEQ ID NO:1);
the VH CDR2 comprises the amino acid sequence NPYNDG (SEQ ID NO:2); and
the VH CDR3 comprises the amino acid sequence GTYYYGTRVFDY (SEQ ID NO:3); and
wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RSSKSLQNVNGNTYLY (SEQ ID NO:4);
the VL CDR2 comprises the amino acid sequence RMSNLNS (SEQ ID NO:5); and
the VL CDR3 comprises the amino acid sequence MQHLEYPIT (SEQ ID NO:6).

80. The antibody that binds to human CD19 for use according to claim 78 or claim 79, wherein the VH domain comprises the amino acid sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS (SEQ ID NO:7) and the VL domain comprises the amino acid sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO:8).

81. The antibody that binds to human CD19 for use according to any one of claims 78 to 80, wherein the antibody comprises a heavy chain region of EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPR

~~EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDG~~
~~SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 11)~~
~~and a light chain~~

~~region of~~

~~DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12).~~

~~82. The antibody that binds to human CD19 for use according to any one of claims 78 to 81, wherein the human subject has a non-Hodgkin lymphoma.~~

~~83. The antibody that binds to human CD19 for use according to claim 82, wherein the non-Hodgkin lymphoma is follicular lymphoma.~~

~~84. The antibody that binds to human CD19 for use according to claim 83, wherein the follicular lymphoma is relapsed/refractory follicular lymphoma.~~

~~85. The antibody that binds to human CD19 for use according to claim 83 or 84, wherein the follicular lymphoma is histologically confirmed Grade 1, 2, or 3a follicular lymphoma.~~

~~86. The antibody that binds to human CD19 for use according to claim 82, wherein the non-Hodgkin lymphoma is marginal zone lymphoma.~~

~~87. The antibody that binds to human CD19 for use according to claim 86, wherein the marginal zone lymphoma is relapsed/refractory marginal zone lymphoma.~~

~~88. The antibody that binds to human CD19 for use according to claim 86 or 87, wherein the marginal zone lymphoma is histologically confirmed nodal marginal zone lymphoma, splenic marginal zone lymphoma, or extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue.~~

~~89. The antibody that binds to human CD19 for use according to claim 82, wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma.~~

~~90. The antibody that binds to human CD19 for use according to claim 89, wherein the diffuse large B-cell lymphoma is relapsed/refractory diffuse large B-cell lymphoma.~~

~~91. The antibody that binds to human CD19 for use according to claim 82, wherein the non-Hodgkin lymphoma is small lymphocytic lymphoma.~~

92. The antibody that binds to human CD19 for use according to claim 82, wherein the non-Hodgkin lymphoma is mucosa-associated lymphoid tissue lymphoma.

93. The antibody that binds to human CD19 for use according to claim 82, wherein the non-Hodgkin lymphoma is Burkitt's lymphoma.

94. The antibody that binds to human CD19 for use according to claim 29, wherein the non-Hodgkin lymphoma is mantle cell lymphoma.

95. The antibody that binds to human CD19 for use according to any one of claims 25 to 28, wherein the human subject has chronic lymphocytic leukemia.

96. The antibody that binds to human CD19 for use according to any one of claims 78 to 81, wherein the human subject has acute lymphoblastic leukemia.

97. The antibody that binds to human CD19 for use according to any one of claims 78 to 96, wherein the antibody is administered intravenously.

98. The antibody that binds to human CD19 for use according to any one of claims 78 to 96, wherein the antibody is administered intravenously at a dose of 12 mg/kg.

99. The antibody that binds to human CD19 for use according to any one of claims 78 to 96, wherein the antibody is administered intravenously at least once every two weeks at a dose of 12 mg/kg.

100. The antibody that binds to human CD19 for use according to any one of claims 78 to 96, wherein the antibody is administered intravenously at a dose of 12 mg/kg according to the following schedule:
on days 1, 8, 15, and 22 of a first 28-day cycle;
on days 1, 8, 15, and 22 of a second 28-day cycle;
on days 1, 8, 15, and 22 of a third 28-day cycle; and
on days 1 and 15 of a fourth 28-day cycle and on days 1 and 15 of further 28-day cycles thereafter.

~~101. The antibody that binds to human CD19 for use according to any one of claims 78 to 100, wherein rituximab is administered intravenously.~~

~~102. The antibody that binds to human CD19 for use according to any one of claims 78 to 100, wherein rituximab is administered intravenously at a dose of 375 mg/m^2.~~

~~103. The antibody that binds to human CD19 for use according to any one of claims 78 to 100, wherein rituximab is administered intravenously at a dose of 375 mg/m^2 according to the following schedule:~~
~~on days 1, 8, 15, and 22 of a first 28-day cycle; and~~
~~on day 1 of a second 28-day cycle and on day 1 of further 28-day cycles thereafter.~~

~~104. The antibody that binds to human CD19 for use according to any one of claims 78 to 103, wherein lenalidomide is administered orally.~~

~~105. The antibody that binds to human CD19 for use according to any one of claims 78 to 103, wherein lenalidomide is administered orally at a dose of 20 mg.~~

~~106. The antibody that binds to human CD19 for use according to any one of claims 78 to 103, wherein lenalidomide is administered orally at a dose of 20 mg on days 1-21 of repeated 28-day cycles.~~